Early antiviral treatment response in HBeAg-positive chronic HBV infected-patients with high viral load and normal ALT
10.3760/cma.j.cn501113-20230313-00108
- VernacularTitle:HBeAg阳性且高病毒载量ALT正常慢性HBV感染患者应尽早抗病毒治疗
- Author:
Yan HUANG
1
;
Bingying DU
;
Qing XIE
Author Information
1. 上海交通大学医学院附属瑞金医院感染科，上海 200025
- Keywords:
Chronic hepatitis B;
Immune-tolerant phase;
Antiviral therapy
- From:
Chinese Journal of Hepatology
2023;31(3):233-237
- CountryChina
- Language:Chinese
-
Abstract:
The diagnosis and treatment rates of hepatitis B virus (HBV) infection in China in 2020 were 22.1% and 15.0%, respectively, according to the Polaris Observatory HBV Collaborators report. This is still far below the World Health Organization's 2030 hepatitis B elimination target (90% and 80%, respectively, for the diagnosis and treatment rates). Although China has promulgated and implemented a series of policies to eliminate the hepatitis B virus, there are still many HBV infected patients who need to be detected and treated. It has been contoversial whether HBeAg-positive chronic HBV infected-patients with high viral load and normal alanine aminotransferase (ALT), also known as the "immune-tolerant phase," should receive anti-HBV therapy. Hepatologists should pay attention to the patient population known as "immune tolerant," as well as the continuous accumulation of evidence-based medical evidence for early antiviral therapy response. The current focus is on discussing the pros and cons of receiving and recommending anti-HBV therapy at this time for the management of these patients.
